• World’s largest non-profit organisation dedicated to commercial use of life science laboratory research tools, reagents, and materials 
• Wholly owned subsidiary of Cancer Research UK 
• Partnerships with more than 150 Technology Transfer Offices, over 2000 researchers and more than 200 life science companiesworldwide

Partnership with Charles University 

• Sale of compounds and other research tools developed at CUNI through Ximbio’s portfolio (Ximbio.com) 
• Ximbio pays CUNI 60 % of revenue generated by offered compounds
• Researchers are entitled to up to 55 % of the received sum based on Rector’s Directive No. 46/2018 
• Requires minimum effort on researcher’s side 
• Preparation of compounds in required commercial amounts takes place in Ximbio’s labs based on provided preparation protocols
• Opportunity to repurpose compounds and tools developed in research projects and with no further use 
• Interest in compounds and tools both with and without IP protection

• Monoclonal Antibodies 
• Polyclonal Antibodies
• Cell Lines
• Mouse Models
• Small Molecules
• Vectors
• Peptides and Proteins
• Zebrafish
• Recombinant Antibodies
• Lab Consumables
• Bacteria

• Structure or any other form of characterisation of offered research tools
• Preparation protocols
• Optional: 
• Small samples for analyses
• Can be crude (Ximbio will purify them themselves)
• Data from analyses, biological testing, etc.
• Information on original intended use and other potential applications
• Information on expected biological activity
• Other available relevant documentation

Dr. Antonín Králík
Analyst and Patent Specialist
Phone: +420 771 134 090
E-Mail: kralik@cuip.cz